Author:
Rigo-Bonnin Raúl,Tiraboschi Juan Manuel,Álvarez-Álvarez Marta,Pérez-Fernández Gloria Ainara,Sanjuás-Iglesias Mercedes,Scévola Sofía,Niubó Jordi,Videla Sebastián,Podzamczer Daniel
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference20 articles.
1. Initial antiretroviral therapy in an integrase inhibitor era: can we do better?;Kelly;Infect. Dis. Clin. North. Am.,2019
2. Bictegravir;Spagnuolo;Curr. Opin. HIV AIDS.,2018
3. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile;Tsiang;Antimicrob. Agents Chemother.,2016
4. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
5. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A review in HIV-1 infection;Deeks;Drugs.,2018
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献